← Leaderboards
Piyush Agarwal
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasm Of Urinary Bladder”
- David Heimbrook · Leidos Biomedical Research, Inc.$89,819,252
- Walter John Curran · Thomas Jefferson University$36,890,150
- Norman Wolmark · Nsabp Foundation, Inc.$33,598,810
- Robert S Mannel · University Of Oklahoma Hlth Sciences Ctr$33,598,810
- Quynh-Thu X Le · Stanford University$23,198,964
- Larry Arthur$21,899,494
Research focus
Malignant Neoplasm Of Urinary BladderTumorCell LineCancer Cell LineBladderPharmaceutical PreparationsCellsBladder NeoplasmInhibitor/AntagonistMuscleMalignant NeoplasmsWomanCancer CellBaseResponsePharmacotherapyPre-ClinicalUrinaryOverexpressionRecurrenceAnimalsStandard Of CarePreventIn Vitro
Grant awards (44)
Molecular Targeted Photoimmunotherapy for Bladder Cancer$288,854
ZIA · FY2019 · CA · contact PI
Targeting Metabolic Pathways in Bladder Cancer$240,712
ZIA · FY2019 · CA · contact PI
Investigation of Epigenetic Modifiers in Bladder Cancer$240,712
ZIA · FY2019 · CA · contact PI
High Throughput Screening of Agents in Bladder Cancer Cell Lines$96,285
ZIC · FY2019 · CA · contact PI
A Phase I Combination Study of Durvalumab and Vicinium in BCG refractory NMIBC$48,142
ZIA · FY2019 · CA · contact PI
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus$48,142
ZIA · FY2019 · CA · contact PI
Molecular Targeted Photoimmunotherapy for Bladder Cancer$260,828
ZIA · FY2018 · CA · contact PI
Targeting Metabolic Pathways in Bladder Cancer$217,357
ZIA · FY2018 · CA · contact PI
Investigation of Epigenetic Modifiers in Bladder Cancer$217,357
ZIA · FY2018 · CA · contact PI
High Throughput Screening of Agents in Bladder Cancer Cell Lines$86,943
ZIC · FY2018 · CA · contact PI
A Phase I Combination Study of Durvalumab and Vicinium in BCG refractory NMIBC$43,472
ZIA · FY2018 · CA · contact PI
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus$43,472
ZIA · FY2018 · CA · contact PI
Molecular Targeted Photoimmunotherapy for Bladder Cancer$271,873
ZIA · FY2017 · CA · contact PI
Targeting Metabolic Pathways in Bladder Cancer$181,249
ZIA · FY2017 · CA · contact PI
Evaluation of Protein Kinase D1 in Bladder Cancer as a possible oncogene$181,249
ZIA · FY2017 · CA · contact PI
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus$135,937
ZIA · FY2017 · CA · contact PI
A Phase I Combination Study of Durvalumab and Vicinium in BCG refractory NMIBC$45,312
ZIA · FY2017 · CA · contact PI
Investigation of Epigenetic Modifiers in Bladder Cancer$45,312
ZIA · FY2017 · CA · contact PI
High Throughput Screening of Agents in Bladder Cancer Cell Lines$45,312
ZIC · FY2017 · CA · contact PI
Molecular Targeted Photoimmunotherapy for Bladder Cancer$785,005
ZIA · FY2016 · CA · contact PI
Evaluation of Protein Kinase D1 in Bladder Cancer as a possible oncogene$348,891
ZIA · FY2016 · CA · contact PI
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus$261,668
ZIA · FY2016 · CA · contact PI
Targeting Metabolic Pathways in Bladder Cancer$157,000
ZIA · FY2016 · CA · contact PI
Investigation of Epigenetic Modifiers in Bladder Cancer$87,222
ZIA · FY2016 · CA · contact PI
High Throughput Screening of Agents in Bladder Cancer Cell Lines$87,222
ZIC · FY2016 · CA · contact PI
Contribution of Y-specific Genes to Bladder Cancer$17,444
ZIA · FY2016 · CA · contact PI
Molecular Targeted Photoimmunotherapy for Bladder Cancer$437,764
ZIA · FY2015 · CA · contact PI
Evaluation of Protein Kinase D1 in Bladder Cancer as a possible oncogene$194,563
ZIA · FY2015 · CA · contact PI
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus$145,921
ZIA · FY2015 · CA · contact PI
Contribution of Y-specific Genes to Bladder Cancer$97,281
ZIA · FY2015 · CA · contact PI
Investigation of Epigentic Modifiers in Bladder Cancer$48,640
ZIA · FY2015 · CA · contact PI
High Throughput Screening of Agents in Bladder Cancer Cell Lines$48,640
ZIC · FY2015 · CA · contact PI
Molecular Targeted Photoimmunotherapy for Bladder Cancer$569,459
ZIA · FY2014 · CA · contact PI
Contribution of Y-specific Genes to Bladder Cancer$253,092
ZIA · FY2014 · CA · contact PI
Evaluation of Protein Kinase D1 in Bladder Cancer as a Novel Tumor Suppressor$164,511
ZIA · FY2014 · CA · contact PI
High Throughput Screening of Agents in Bladder Cancer Cell Lines$126,547
ZIC · FY2014 · CA · contact PI
Investigation of Epigentic Modifiers in Bladder Cancer$63,273
ZIA · FY2014 · CA · contact PI
Androgen Receptor in Bladder Cancer$63,273
ZIA · FY2014 · CA · contact PI
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus$25,309
ZIA · FY2014 · CA · contact PI
Molecular Targeted Photoimmunotherapy for Bladder Cancer$281,478
ZIA · FY2013 · CA · contact PI
Androgen Receptor in Bladder Cancer$52,777
ZIA · FY2013 · CA · contact PI
High Throughput Screening of Agents in Bladder Cancer Cell Lines$10,555
ZIC · FY2013 · CA · contact PI
A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus$7,036
ZIA · FY2013 · CA · contact PI
Molecular Targeted Photoimmunotherapy for Bladder Cancer$616,957
ZIA · FY2012 · CA · contact PI